These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 24977733)

  • 1. Comparative sensitivity of commercially available aPTT reagents to mulga snake (Pseudechis australis) venom.
    Lincz LF; Scorgie FE; Johnston CI; O'Leary M; Prasad R; Seldon M; Favaloro E; Isbister GK
    Pathology; 2014 Aug; 46(5):444-9. PubMed ID: 24977733
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mulga snake (Pseudechis australis) envenoming: a spectrum of myotoxicity, anticoagulant coagulopathy, haemolysis and the role of early antivenom therapy - Australian Snakebite Project (ASP-19).
    Johnston CI; Brown SG; O'Leary MA; Currie BJ; Greenberg R; Taylor M; Barnes C; White J; Isbister GK;
    Clin Toxicol (Phila); 2013 Jun; 51(5):417-24. PubMed ID: 23586640
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Australian mulga snake (Pseudechis australis: Elapidae): report of a large case series of bites and review of current knowledge.
    Razavi S; Weinstein SA; Bates DJ; Alfred S; White J
    Toxicon; 2014 Jul; 85():17-26. PubMed ID: 24726467
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics and pharmacodynamics of the myotoxic venom of Pseudechis australis (mulga snake) in the anesthetised rat.
    Hart AJ; Hodgson WC; O'Leary M; Isbister GK
    Clin Toxicol (Phila); 2014 Jul; 52(6):604-10. PubMed ID: 24940643
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detection of shortened activated partial thromboplastin times: an evaluation of different commercial reagents.
    Ten Boekel E; Böck M; Vrielink GJ; Liem R; Hendriks H; de Kieviet W
    Thromb Res; 2007; 121(3):361-7. PubMed ID: 17568658
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of dabigatran on the activated partial thromboplastin time and thrombin time as determined by the Hemoclot thrombin inhibitor assay in patient plasma samples.
    Hapgood G; Butler J; Malan E; Chunilal S; Tran H
    Thromb Haemost; 2013 Aug; 110(2):308-15. PubMed ID: 23783268
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recommendations for appropriate activated partial thromboplastin time reagent selection and utilization.
    Fritsma GA; Dembitzer FR; Randhawa A; Marques MB; Van Cott EM; Adcock-Funk D; Peerschke EI
    Am J Clin Pathol; 2012 Jun; 137(6):904-8. PubMed ID: 22586049
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the activated partial thromboplastin time assay for clinical monitoring of PEGylated recombinant factor VIII (BAY 94-9027) for haemophilia A.
    Gu JM; Ramsey P; Evans V; Tang L; Apeler H; Leong L; Murphy JE; Laux V; Myles T
    Haemophilia; 2014 Jul; 20(4):593-600. PubMed ID: 24471985
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of a sensitive enzyme immunoassay for measuring taipan venom in serum.
    Kulawickrama S; O'Leary MA; Hodgson WC; Brown SG; Jacoby T; Davern K; Isbister GK
    Toxicon; 2010 Jul; 55(8):1510-8. PubMed ID: 20223258
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative effects of the human protein C activator, Protac, on the activated partial thromboplastin clotting times of plasmas, with special reference to the dog.
    Johnstone IB; Martin CA
    Can J Vet Res; 2000 Apr; 64(2):117-22. PubMed ID: 10805251
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Basic coagulation tests as surrogates of dabigatran levels in a pre-operative setting: Analysis of five activated partial thromboplastin time reagents and thrombin time.
    Dubé C; Douketis JD; Moffat KA; Schulman S; Blais N
    Thromb Res; 2018 Nov; 171():62-67. PubMed ID: 30261356
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multilaboratory testing of thrombophilia: current and past practice in Australasia as assessed through the Royal College of Pathologists of Australasia Quality Assurance Program for Hematology.
    Favaloro EJ; Bonar R; Sioufi J; Wheeler M; Low J; Aboud M; Duncan E; Smith J; Exner T; Lloyd J; Marsden K;
    Semin Thromb Hemost; 2005 Feb; 31(1):49-58. PubMed ID: 15706475
    [TBL] [Abstract][Full Text] [Related]  

  • 13. APTT reagent with ellagic acid as activator shows adequate lupus anticoagulant sensitivity in comparison to silica-based reagent.
    Kumano O; Ieko M; Naito S; Yoshida M; Takahashi N
    J Thromb Haemost; 2012 Nov; 10(11):2338-43. PubMed ID: 22909048
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Performance of Platelin LS and dilute Russell's viper venom for the screening of lupus anticoagulant in patients with venous thromboembolism.
    Morelli VM; Rodrigues CA; Noguti MA; Matos MF; da Silveira RC; Ribeiro AA; Lourenço DM
    Blood Coagul Fibrinolysis; 2007 Jul; 18(5):401-5. PubMed ID: 17581313
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Usefulness of cumulative summation of differences method for determining APTT reagent suitability.
    Findlater SH
    Clin Lab Sci; 2012; 25(3):142-8. PubMed ID: 22953513
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of coagulometric assays in the assessment of protein C anticoagulant activity; variable sensitivity of commercial APTT reagents to the cofactor effect of protein S.
    D'Angelo SV; Gilardoni F; D'Angelo A
    Thromb Haemost; 1989 Nov; 62(3):861-7. PubMed ID: 2531939
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro sensitivity of different activated partial thromboplastin time reagents to mild clotting factor deficiencies.
    Toulon P; Eloit Y; Smahi M; Sigaud C; Jambou D; Fischer F; Appert-Flory A
    Int J Lab Hematol; 2016 Aug; 38(4):389-96. PubMed ID: 27185477
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinically applicable laboratory end-points for treating snakebite coagulopathy.
    Isbister GK; Williams V; Brown SG; White J; Currie BJ;
    Pathology; 2006 Dec; 38(6):568-72. PubMed ID: 17393987
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Determination of APTT factor sensitivity--the misguiding guideline.
    Lawrie AS; Kitchen S; Efthymiou M; Mackie IJ; Machin SJ
    Int J Lab Hematol; 2013 Dec; 35(6):652-7. PubMed ID: 23718922
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparison of the sensitivity of APTT reagents to the effects of enoxaparin, a low-molecular weight heparin.
    Ip BK; Thomson AR; Moriarty HT
    Pathology; 2001 Aug; 33(3):347-52. PubMed ID: 11523938
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.